Dermot Ryan1, Heath Heatley2, Liam G Heaney3, David J Jackson4, Paul E Pfeffer5, John Busby3, Andrew N Menzies-Gow6, Rupert Jones7, Trung N Tran8, Mona Al-Ahmad9, Vibeke Backer10, Manon Belhassen11, Sinthia Bosnic-Anticevich12, Arnaud Bourdin13, Lakmini Bulathsinhala14, Victoria Carter14, Isha Chaudhry2, Neva Eleangovan14, J Mark FitzGerald15, Peter G Gibson16, Naeimeh Hosseini17, Alan Kaplan18, Ruth B Murray17, Chin Kook Rhee19, Eric Van Ganse11, David B Price20. 1. Usher Institute, University of Edinburgh, United Kingdom. 2. Observational and Pragmatic Research Institute, Singapore, Singapore. 3. UK Severe Asthma Network and National Registry, Queen's University Belfast, Belfast, Northern Ireland. 4. UK Severe Asthma Network and National Registry, Guy's and St Thomas' NHS Trust and Division of Asthma, Allergy & Lung Biology, King's College London, London, United Kingdom. 5. UK Severe Asthma Network, Barts Health NHS Trust and Queen Mary University of London, London, United Kingdom. 6. UK Severe Asthma Network and National Registry, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom. 7. Faculty of Health, University of Plymouth, Plymouth, United Kingdom. 8. AstraZeneca, Gaithersburg, MD. 9. Al-Rashed Allergy Center, Ministry of Health, Microbiology Department, Faculty of Medicine, Kuwait University, Kuwait. 10. Department of ENT & Centre for Physical Activity Research, Rigshospitalet and Copenhagen University, Copenhagen, Denmark. 11. PELyon, HESPER 7425, Claude Bernard University, Lyon, France. 12. Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia. 13. Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France. 14. Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom. 15. Centre for Lung Health, Vancouver, Canada. 16. Australian Severe Asthma Network, Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, NSW, Australia; Hunter Medical Research Institute, Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton Heights, NSW, Australia. 17. Optimum Patient Care, Cambridge, United Kingdom. 18. Family Physician Airways Group of Canada, Stouffville, ON, Canada; University of Toronto, Toronto, ON, Canada. 19. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. 20. Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom; Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom. Electronic address: dprice@opri.sg.
Abstract
BACKGROUND: Severe asthma may be underrecognized in primary care. OBJECTIVE: Identify and quantify patients with potential severe asthma (PSA) in UK primary care, the proportion not referred, and compare primary care patients with PSA with patients with confirmed severe asthma from UK tertiary care. METHODS: This was a historical cohort study including patients from the Optimum Patient Care Research Database (aged ≥16 years, active asthma diagnosis pre-2014) and UK patients in the International Severe Asthma Registry (UK-ISAR aged ≥18 years, confirmed severe asthma in tertiary care). In the OPCRD, PSA was defined as Global INitiative for Asthma 2018 step 4 treatment and 2 or more exacerbations/y or at Global INitiative for Asthma step 5. The proportion of these patients and their referral status in the last year were quantified. Demographic and clinical characteristics of groups were compared. RESULTS: Of 207,557 Optimum Patient Care Research Database patients with asthma, 16,409 (8%) had PSA. Of these, 72% had no referral/specialist review in the past year. Referred patients with PSA tended to have greater prevalence of inhaled corticosteroid/long-acting β2-agonist add-ons (54.1 vs 39.8%), and experienced significantly (P < .001) more exacerbations per year (median, 3 vs 2/y), worse asthma control, and worse lung function (% predicted postbronchodilator FEV1/forced vital capacity, 0.69 vs 0.72) versus nonreferred patients. Confirmed patients with severe asthma (ie, UK patients in the International Severe Asthma Registry) were younger (51 vs 65 years; P < .001), and significantly (P < .001) more likely to have uncontrolled asthma (91.4% vs 62.5%), a higher exacerbation rate (4/y [initial assessment] vs 3/y), use inhaled corticosteroid/long-acting β2-agonist add-ons (67.7% vs 54.1%), and have nasal polyposis (24.2% vs 6.8) than referred patients with PSA. CONCLUSIONS: Large numbers of patients with PSA in the United Kingdom are underrecognized in primary care. These patients would benefit from a more systematic assessment in primary care and possible specialist referral.
BACKGROUND: Severe asthma may be underrecognized in primary care. OBJECTIVE: Identify and quantify patients with potential severe asthma (PSA) in UK primary care, the proportion not referred, and compare primary care patients with PSA with patients with confirmed severe asthma from UK tertiary care. METHODS: This was a historical cohort study including patients from the Optimum Patient Care Research Database (aged ≥16 years, active asthma diagnosis pre-2014) and UK patients in the International Severe Asthma Registry (UK-ISAR aged ≥18 years, confirmed severe asthma in tertiary care). In the OPCRD, PSA was defined as Global INitiative for Asthma 2018 step 4 treatment and 2 or more exacerbations/y or at Global INitiative for Asthma step 5. The proportion of these patients and their referral status in the last year were quantified. Demographic and clinical characteristics of groups were compared. RESULTS: Of 207,557 Optimum Patient Care Research Database patients with asthma, 16,409 (8%) had PSA. Of these, 72% had no referral/specialist review in the past year. Referred patients with PSA tended to have greater prevalence of inhaled corticosteroid/long-acting β2-agonist add-ons (54.1 vs 39.8%), and experienced significantly (P < .001) more exacerbations per year (median, 3 vs 2/y), worse asthma control, and worse lung function (% predicted postbronchodilator FEV1/forced vital capacity, 0.69 vs 0.72) versus nonreferred patients. Confirmed patients with severe asthma (ie, UK patients in the International Severe Asthma Registry) were younger (51 vs 65 years; P < .001), and significantly (P < .001) more likely to have uncontrolled asthma (91.4% vs 62.5%), a higher exacerbation rate (4/y [initial assessment] vs 3/y), use inhaled corticosteroid/long-acting β2-agonist add-ons (67.7% vs 54.1%), and have nasal polyposis (24.2% vs 6.8) than referred patients with PSA. CONCLUSIONS: Large numbers of patients with PSA in the United Kingdom are underrecognized in primary care. These patients would benefit from a more systematic assessment in primary care and possible specialist referral.
Authors: Kerry L Hancock; Sinthia Bosnic-Anticevich; John D Blakey; Mark Hew; Li Ping Chung; Biljana Cvetkovski; Scott Claxton; Peter Del Fante; Eve Denton; Joe Doan; Kanchanamala Ranasinghe; Lucy Morgan; Anita Sharma; Peter K Smith; Deb Stewart; Philip J Thompson; Russell Wiseman; John W Upham; Kwok Y Yan; Victoria Carter; Kiranjeet Dhillon; Florian Heraud; Thao Le; Rebecca Vella; David Price Journal: Pragmat Obs Res Date: 2022-07-05
Authors: John Busby; David Price; Riyad Al-Lehebi; Sinthia Bosnic-Anticevich; Job F M van Boven; Benjamin Emmanuel; J Mark FitzGerald; Mina Gaga; Susanne Hansen; Mark Hew; Takashi Iwanaga; Désirée Larenas Linnemann; Bassam Mahboub; Patrick Mitchell; Daniela Morrone; Jonathan Pham; Celeste Porsbjerg; Nicolas Roche; Eileen Wang; Neva Eleangovan; Liam G Heaney Journal: J Asthma Allergy Date: 2021-11-10
Authors: David Price; Andrew Menzies-Gow; Claus Bachert; Giorgio Walter Canonica; Janwillem Kocks; Asif H Khan; Fen Ye; Paul J Rowe; Yufang Lu; Siddhesh Kamat; Victoria Carter; Jaco Voorham Journal: J Asthma Allergy Date: 2021-09-29
Authors: David J Jackson; Praveen Akuthota; Rebeca Andradas; Albert J Bredenoord; Amanda Cordell; Sarah Gray; Joyce Kullman; Sameer K Mathur; Ian Pavord; Florence Roufosse; Christian Rubio; Irena Clisson Rusek; Dagmar Simon; Mary Jo Strobel; Tonya Winders Journal: Adv Ther Date: 2022-04-30 Impact factor: 4.070
Authors: Helena Backman; Caroline Stridsman; Linnea Hedman; Lina Rönnebjerg; Bright I Nwaru; Thomas Sandström; Hannu Kankaanranta; Anne Lindberg; Eva Rönmark Journal: J Asthma Allergy Date: 2022-10-10
Authors: Katrina A D'Urzo; Itamar E Tamari; Kenneth R Chapman; M Reza Maleki-Yazdi; Michelle Greiver; Ross Eg Upshur; Lana Biro; Braden O'Neill; Rahim Moineddin; Babak Aliarzadeh; Kulamakan Kulasegaram; Teresa To; Anthony D D'Urzo Journal: BMJ Open Date: 2022-03-24 Impact factor: 2.692